HJ Research delivers in-depth insights on the global Myeloproliferative Disorders Drugs market in its upcoming report titled, Global Myeloproliferative Disorders Drugs Market Report 2018-2029. According to this study, the global Myeloproliferative Disorders Drugs market is estimated to be valued at XX Million US$ in 2023 and is projected to reach XX Million US$ by 2029, expanding at a CAGR of XX% during the forecast period. The report on Myeloproliferative Disorders Drugs market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc.
This report studies the Myeloproliferative Disorders Drugs market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Myeloproliferative Disorders Drugs industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Myeloproliferative Disorders Drugs industry.
Global Myeloproliferative Disorders Drugs market: competitive landscape analysis
This report contains the major manufacturers analysis of the global Myeloproliferative Disorders Drugs industry. By understanding the operations of these manufacturers (revenue and gross margin from 2018 to 2023), the reader can understand the strategies and collaborations that the manufacturers are focusing on combat competition in the market.
Global Myeloproliferative Disorders Drugs market: types and end industries analysis
The research report includes specific segments such as end industries and product types of Myeloproliferative Disorders Drugs. The report provides market size for each type and end industry from 2018 to 2023. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global Myeloproliferative Disorders Drugs market: regional analysis
Geographically, this report is segmented into several key countries, with market size, growth rate of Myeloproliferative Disorders Drugs in these countries from 2018 to 2023, which covering United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, China, Japan, Korea, India, Australia, Indonesia, Vietnam, Turkey, Saudi Arabia, South Africa, Egypt, Brazil, Mexico, Argentina, Colombia.
Key players in global Myeloproliferative Disorders Drugs market include:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson & Johnson
Market segmentation, by product types:
Ph+ CML
Ph- MPN
Market segmentation, by applications:
Hospitals
Pharmacy
1 Industry Overview of Myeloproliferative Disorders Drugs
1.1 Research Scope
1.2 Market Segmentation by Types of Myeloproliferative Disorders Drugs
1.3 Market Segmentation by End Users of Myeloproliferative Disorders Drugs
1.4 Market Dynamics Analysis of Myeloproliferative Disorders Drugs
1.4.1 Market Drivers
1.4.2 Market Challenges
1.4.3 Market Opportunities
1.4.4 Porter’s Five Forces
2 Major Manufacturers Analysis of Myeloproliferative Disorders Drugs Industry
2.1 Celgene
2.1.1 Company Overview
2.1.2 Main Products and Specifications
2.1.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.1.4 Contact Information
2.2 Bristol-Myers Squibb
2.2.1 Company Overview
2.2.2 Main Products and Specifications
2.2.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.2.4 Contact Information
2.3 Gamida Cell
2.3.1 Company Overview
2.3.2 Main Products and Specifications
2.3.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.3.4 Contact Information
2.4 Incyte
2.4.1 Company Overview
2.4.2 Main Products and Specifications
2.4.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.4.4 Contact Information
2.5 Geron
2.5.1 Company Overview
2.5.2 Main Products and Specifications
2.5.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.5.4 Contact Information
2.6 Promedior
2.6.1 Company Overview
2.6.2 Main Products and Specifications
2.6.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.6.4 Contact Information
2.7 Johnson & Johnson
2.7.1 Company Overview
2.7.2 Main Products and Specifications
2.7.3 Myeloproliferative Disorders Drugs Revenue and Gross Margin (2018-2023)
2.7.4 Contact Information
3 Global Myeloproliferative Disorders Drugs Market Analysis by Regions, Manufacturers, Types and End Users
3.1 Global Sales Revenue of Myeloproliferative Disorders Drugs by Regions (2018-2023)
3.2 Global Sales Revenue of Myeloproliferative Disorders Drugs by Manufacturers (2018-2023)
3.3 Global Sales Revenue of Myeloproliferative Disorders Drugs by Types (2018-2023)
3.4 Global Sales Revenue of Myeloproliferative Disorders Drugs by End Users (2018-2023)
4 Northern America Myeloproliferative Disorders Drugs Market Analysis by Countries, Types and End Users
4.1 Northern America Myeloproliferative Disorders Drugs Sales Revenue Analysis by Countries (2018-2023)
4.2 Northern America Myeloproliferative Disorders Drugs Sales Revenue Analysis by Types (2018-2023)
4.3 Northern America Myeloproliferative Disorders Drugs Sales Revenue Analysis by End Users (2018-2023)
4.4 United States Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
4.5 Canada Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5 Europe Myeloproliferative Disorders Drugs Market Analysis by Countries, Types and End Users
5.1 Europe Myeloproliferative Disorders Drugs Sales Revenue Analysis by Countries (2018-2023)
5.2 Europe Myeloproliferative Disorders Drugs Sales Revenue Analysis by Types (2018-2023)
5.3 Europe Myeloproliferative Disorders Drugs Sales Revenue Analysis by End Users (2018-2023)
5.4 Germany Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.5 France Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.6 UK Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.7 Italy Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.8 Russia Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.9 Spain Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
5.10 Netherlands Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6 Asia Pacific Myeloproliferative Disorders Drugs Market Analysis by Countries, Types and End Users
6.1 Asia Pacific Myeloproliferative Disorders Drugs Sales Revenue Analysis by Countries (2018-2023)
6.2 Asia Pacific Myeloproliferative Disorders Drugs Sales Revenue Analysis by Types (2018-2023)
6.3 Asia Pacific Myeloproliferative Disorders Drugs Sales Revenue Analysis by End Users (2018-2023)
6.4 China Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.5 Japan Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.6 Korea Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.7 India Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.8 Australia Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.9 Indonesia Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
6.10 Vietnam Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
7 Latin America Myeloproliferative Disorders Drugs Market Analysis by Countries, Types and End Users
7.1 Latin America Myeloproliferative Disorders Drugs Sales Revenue Analysis by Countries (2018-2023)
7.2 Latin America Myeloproliferative Disorders Drugs Sales Revenue Analysis by Types (2018-2023)
7.3 Latin America Myeloproliferative Disorders Drugs Sales Revenue Analysis by End Users (2018-2023)
7.4 Brazil Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
7.5 Mexico Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
7.6 Argentina Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
7.7 Colombia Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
8 Middle East & Africa Myeloproliferative Disorders Drugs Market Analysis by Countries, Types and End Users
8.1 Middle East & Africa Myeloproliferative Disorders Drugs Sales Revenue Analysis by Countries (2018-2023)
8.2 Middle East & Africa Myeloproliferative Disorders Drugs Sales Revenue Analysis by Types (2018-2023)
8.3 Middle East & Africa Myeloproliferative Disorders Drugs Sales Revenue Analysis by End Users (2018-2023)
8.4 Turkey Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
8.5 Saudi Arabia Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
8.6 South Africa Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
8.7 Egypt Myeloproliferative Disorders Drugs Sales Revenue Analysis (2018-2023)
9 Marketing Channel, Distributors and Traders Analysis
9.1 Marketing Channel
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Distributors and Traders
10 Global Myeloproliferative Disorders Drugs Market Forecast by Regions, Countries, Manufacturers, Types and End Users
10.1 Global Sales Revenue Forecast of Myeloproliferative Disorders Drugs by Regions (2024-2029)
10.2 Global Sales Revenue Forecast of Myeloproliferative Disorders Drugs by Types (2024-2029)
10.3 Global Sales Revenue Forecast of Myeloproliferative Disorders Drugs by End Users (2024-2029)
10.4 Global Revenue Forecast of Myeloproliferative Disorders Drugs by Countries (2024-2029)
10.4.1 United States Revenue Forecast (2024-2029)
10.4.2 Canada Revenue Forecast (2024-2029)
10.4.3 Germany Revenue Forecast (2024-2029)
10.4.4 France Revenue Forecast (2024-2029)
10.4.5 UK Revenue Forecast (2024-2029)
10.4.6 Italy Revenue Forecast (2024-2029)
10.4.7 Russia Revenue Forecast (2024-2029)
10.4.8 Spain Revenue Forecast (2024-2029)
10.4.9 Netherlands Revenue Forecast (2024-2029)
10.4.10 China Revenue Forecast (2024-2029)
10.4.11 Japan Revenue Forecast (2024-2029)
10.4.12 Korea Revenue Forecast (2024-2029)
10.4.13 India Revenue Forecast (2024-2029)
10.4.14 Australia Revenue Forecast (2024-2029)
10.4.15 Indonesia Revenue Forecast (2024-2029)
10.4.16 Vietnam Revenue Forecast (2024-2029)
10.4.17 Brazil Revenue Forecast (2024-2029)
10.4.18 Mexico Revenue Forecast (2024-2029)
10.4.19 Argentina Revenue Forecast (2024-2029)
10.4.20 Colombia Revenue Forecast (2024-2029)
10.4.21 Turkey Revenue Forecast (2024-2029)
10.4.22 Saudi Arabia Revenue Forecast (2024-2029)
10.4.23 South Africa Revenue Forecast (2024-2029)
10.4.24 Egypt Revenue Forecast (2024-2029)
11 Industry Chain Analysis of Myeloproliferative Disorders Drugs
11.1 Upstream Analysis of Myeloproliferative Disorders Drugs
11.2 Downstream Major Consumers Analysis of Myeloproliferative Disorders Drugs
11.3 Major Suppliers of Myeloproliferative Disorders Drugs with Contact Information
11.4 Supply Chain Relationship Analysis of Myeloproliferative Disorders Drugs
12 Myeloproliferative Disorders Drugs New Project Investment Feasibility Analysis
12.1 Myeloproliferative Disorders Drugs New Project SWOT Analysis
12.2 Myeloproliferative Disorders Drugs New Project Investment Feasibility Analysis
12.2.1 Project Name
12.2.2 Investment Budget
12.2.3 Project Product Solutions
12.2.4 Project Schedule
13 Myeloproliferative Disorders Drugs Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.2 References and Data Sources
14.2.1 Primary Sources
14.2.2 Secondary Paid Sources
14.2.3 Secondary Public Sources
14.3 Abbreviations and Units of Measurement
14.4 Author Details
14.5 Disclaimer
Table Types of Myeloproliferative Disorders Drugs
Table End Users of Myeloproliferative Disorders Drugs
Figure Market Drivers Analysis of Myeloproliferative Disorders Drugs
Figure Market Challenges Analysis of Myeloproliferative Disorders Drugs
Figure Market Opportunities Analysis of Myeloproliferative Disorders Drugs
Table Market Drivers Analysis of Myeloproliferative Disorders Drugs
Table Celgene Information List
Figure Myeloproliferative Disorders Drugs Specifications of Celgene
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Celgene (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Celgene (2018-2023)
Table Bristol-Myers Squibb Information List
Figure Myeloproliferative Disorders Drugs Specifications of Bristol-Myers Squibb
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Bristol-Myers Squibb (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Bristol-Myers Squibb (2018-2023)
Table Gamida Cell Information List
Figure Myeloproliferative Disorders Drugs Specifications of Gamida Cell
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Gamida Cell (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Gamida Cell (2018-2023)
Table Incyte Information List
Figure Myeloproliferative Disorders Drugs Specifications of Incyte
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Incyte (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Incyte (2018-2023)
Table Geron Information List
Figure Myeloproliferative Disorders Drugs Specifications of Geron
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Geron (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Geron (2018-2023)
Table Promedior Information List
Figure Myeloproliferative Disorders Drugs Specifications of Promedior
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Promedior (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Promedior (2018-2023)
Table Johnson & Johnson Information List
Figure Myeloproliferative Disorders Drugs Specifications of Johnson & Johnson
Table Myeloproliferative Disorders Drugs Revenue (Million USD) and Gross Margin of Johnson & Johnson (2018-2023)
Figure Myeloproliferative Disorders Drugs Revenue (Million USD) and Global Market Share of Johnson & Johnson (2018-2023)
Table Global Revenue (Million USD) of Myeloproliferative Disorders Drugs by Regions (2018-2023)
Table Global Revenue (Million USD) of Myeloproliferative Disorders Drugs by Manufacturers (2018-2023)
Table Global Revenue (Million USD) of Myeloproliferative Disorders Drugs by Types (2018-2023)
Table Global Revenue (Million USD) of Myeloproliferative Disorders Drugs by End Users (2018-2023)
Table Northern America Myeloproliferative Disorders Drugs Revenue (Million USD) by Countries (2018-2023)
Table Northern America Myeloproliferative Disorders Drugs Revenue (Million USD) by Types (2018-2023)
Table Northern America Myeloproliferative Disorders Drugs Revenue (Million USD) by End Users (2018-2023)
Figure United States Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Canada Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Europe Myeloproliferative Disorders Drugs Revenue (Million USD) by Countries (2018-2023)
Table Europe Myeloproliferative Disorders Drugs Revenue (Million USD) by Types (2018-2023)
Table Europe Myeloproliferative Disorders Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Germany Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure France Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure UK Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Italy Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Russia Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Spain Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Netherlands Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Asia Pacific Myeloproliferative Disorders Drugs Revenue (Million USD) by Countries (2018-2023)
Table Asia Pacific Myeloproliferative Disorders Drugs Revenue (Million USD) by Types (2018-2023)
Table Asia Pacific Myeloproliferative Disorders Drugs Revenue (Million USD) by End Users (2018-2023)
Figure China Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Japan Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Korea Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure India Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Australia Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Indonesia Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Vietnam Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Latin America Myeloproliferative Disorders Drugs Revenue (Million USD) by Countries (2018-2023)
Table Latin America Myeloproliferative Disorders Drugs Revenue (Million USD) by Types (2018-2023)
Table Latin America Myeloproliferative Disorders Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Brazil Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Mexico Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Argentina Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Colombia Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Middle East & Africa Myeloproliferative Disorders Drugs Revenue (Million USD) by Countries (2018-2023)
Table Middle East & Africa Myeloproliferative Disorders Drugs Revenue (Million USD) by Types (2018-2023)
Table Middle East & Africa Myeloproliferative Disorders Drugs Revenue (Million USD) by End Users (2018-2023)
Figure Turkey Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Saudi Arabia Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure South Africa Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Figure Egypt Myeloproliferative Disorders Drugs Revenue (Million USD) and Growth Rate (2018-2023)
Table Global Revenue (Million USD) Forecast of Myeloproliferative Disorders Drugs by Regions (2024-2029)
Table Global Revenue (Million USD) Forecast of Myeloproliferative Disorders Drugs by Types (2024-2029)
Table Global Revenue (Million USD) Forecast of Myeloproliferative Disorders Drugs by End Users (2024-2029)
Table Major Consumers with Contact Information of Myeloproliferative Disorders Drugs
Table Major Suppliers of Myeloproliferative Disorders Drugs with Contact Information
Figure Supply Chain Relationship Analysis of Myeloproliferative Disorders Drugs
Table New Project SWOT Analysis of Myeloproliferative Disorders Drugs
Table Project Appraisal and Financing
Table New Project Construction Period
Table New Project Investment Feasibility Analysis of Myeloproliferative Disorders Drugs
Table Research Programs/Design for This Report
Table Key Data Information from Primary Sources
Table Key Data Information from Secondary Sources
Table Part of Interviewees Record List of Myeloproliferative Disorders Drugs Industry
Table Part of References List of Myeloproliferative Disorders Drugs Industry
Table Units of Measurement List
Table Part of Author Details List of Myeloproliferative Disorders Drugs Industry
HJ Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. At HJ Research, our researchers and domain experts use a unique blend of primary and secondary research, with validation and iterations at every stage, in order to minimize deviation and present the most accurate analysis of the Myeloproliferative Disorders Drugs industry. Critical elements of methodology employed for all our studies include:
Secondary Sources:
The research team first works with national bureau of statistics, national customs, market research association, state information center, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Secondary sources are mainly from press releases, company reports and publications, non-profit organizations, industry associations, government publications, economic and demographic data and customs data. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Primary Research:
In the primary research process, for comprehensive understanding of the Myeloproliferative Disorders Drugs market, it is essential to understand the complete value chain and in order to facilitate this, we collect data from Myeloproliferative Disorders Drugs manufacturers, Myeloproliferative Disorders Drugs raw material suppliers, Myeloproliferative Disorders Drugs distributors as well as buyers. The primary sources from the supply side include Myeloproliferative Disorders Drugs manufacturers, opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the Myeloproliferative Disorders Drugs raw materials suppliers and producers, etc. The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users, and related key executives from various key companies and organizations operating in the global market.
Technical issues and trends are obtained from surveys, technical symposia and trade journals. Technical data is also gathered from intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered.
Statistical Model and Data Analysis:
Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise. Qualitative analysis includes: Myeloproliferative Disorders Drugs industry landscape and trends, Myeloproliferative Disorders Drugs market dynamics and key issues, Myeloproliferative Disorders Drugs technology landscape, market opportunities, porter’s analysis and PESTEL analysis, Myeloproliferative Disorders Drugs competitive landscape and component benchmarking, policy and regulatory scenario. Quantitative analysis includes: Myeloproliferative Disorders Drugs market size and forecast by regions, Myeloproliferative Disorders Drugs market size and forecast by application, Myeloproliferative Disorders Drugs market size and forecast by types, Myeloproliferative Disorders Drugs company market share etc.
Quality Control:
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the HJ Research’s internal quality process.
